The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is a retrospective chart review of sickle cell patients and will include patients whom have received blood transfusions and those whom have not. Of the transfused patients, it will also include those whom have received chelation therapy and those whom have not.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
16 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with Sickle cell anemia
Patients with a diagnosis of Sickle Cell Disease (SCD) and a confirmed genotype
Patients ≥ 16 years of age
Patients with ≥ 6 months of follow-up data available from first SCD treatment at the center after they reach 16 years old
At least one SF reading during a non-acute phase on or after the first SCD treatment at the center after they reach 16 years old
Patients who participated in a clinical trial for an iron chelating medication or in a clinical trial for transfusions for SCD (1) within the six months before the index date or (2) during the patient observation period
Patients with sickle cell trait
Other protocol-defined inclusion/exclusion criteria may apply